GSK hepatitis B drug achieves functional cure in 20%

Good morning, healthcare professional.

Today brings a rare clinical milestone as GSK and Ionis report their experimental hepatitis B treatment achieved a functional cure in nearly one in five patients, alongside major shifts in obesity drug access and regulatory oversight of digital health devices. The FDA has also delayed a key oncology decision following a negative advisory committee vote.

These developments span the full spectrum of healthcare innovation - from breakthrough infectious disease treatments affecting millions globally to formulary decisions that determine which patients can access blockbuster medications. The regulatory landscape continues to evolve rapidly, with implications for both traditional pharmaceuticals and emerging digital health technologies.

In today's healthcare digest:

• GSK and Ionis achieve functional cure milestone in hepatitis B trial
• CVS Caremark restores coverage for Eli Lilly's obesity medications
• FDA postpones AstraZeneca breast cancer drug decision after advisory panel rejection
• Blood pressure monitoring devices surge into market following FDA oversight changes

GSK and Ionis Report Functional Cure in Hepatitis B Breakthrough

GSK and Ionis Pharmaceuticals published clinical trial results showing bepirovirsen, an experimental hepatitis B treatment, achieved a functional cure in nearly 20% of patients. The data, appearing in a major medical journal, marks a significant advance for a disease affecting 296 million people worldwide who currently face lifelong management.

Unpacked:

• The antisense oligonucleotide therapy targets viral RNA, offering a fundamentally different mechanism than existing nucleoside analog treatments.
• Current hepatitis B therapies suppress viral replication but rarely eliminate infection, requiring indefinite daily medication.
• The functional cure rate, while modest, represents measurable disease elimination in a patient population with few curative options.

CVS Caremark Restores Eli Lilly Obesity Drug Coverage

CVS Caremark has restored formulary coverage for Eli Lilly's obesity medications, including injectable Zepbound and newly approved oral pill Foundayo, placing Lilly on equal footing with Novo Nordisk. The decision affects millions of covered lives in the rapidly expanding GLP-1 medication market.

Unpacked:

• The formulary restoration reverses a previous exclusion that had limited patient access to Lilly's obesity treatments.
• Foundayo's oral formulation offers an alternative to injections, potentially expanding the addressable patient population.
• The move intensifies competition in a market projected to exceed $100 billion as demand for weight loss medications continues accelerating.

FDA Delays AstraZeneca Breast Cancer Drug After Advisory Vote

The FDA has postponed its regulatory decision on AstraZeneca's oral breast cancer drug camizestrant following a negative advisory committee vote. The delay extends the review timeline for a medication AstraZeneca had positioned as a priority oncology asset.

Unpacked:

• Advisory committees provide independent expert recommendations, and negative votes typically signal regulatory concerns about efficacy or safety data.
• Camizestrant targets hormone receptor-positive breast cancer, a common subtype affecting hundreds of thousands of patients annually.
• The setback impacts AstraZeneca's oncology pipeline strategy and delays potential treatment options for patients with limited alternatives.

Blood Pressure Devices Flood Market After FDA Relaxes Oversight

Following the FDA's decision to relax regulatory oversight of wellness devices, the market has seen a surge of unvetted blood pressure monitoring technology, including new offerings from companies like Oura. The policy shift allows numerous cuffless devices to reach consumers without traditional FDA review.

Unpacked:

• The FDA reclassified certain health monitoring devices as wellness products, removing premarket review requirements for accuracy validation.
• Cuffless blood pressure monitors use optical sensors and algorithms, technologies with historically variable accuracy compared to traditional cuffs.
• The regulatory change prioritizes market access over clinical validation, raising questions about patient safety and diagnostic reliability.

The Shortlist

• AbbVie secured FDA approval for another ImmunoGen cancer asset as Elahere continues building commercial momentum.

• AstraZeneca gained a second bladder cancer indication for Imfinzi in a key label expansion.

• Kailera Therapeutics reported promising Phase 1 data for its triple-G obesity drug candidate.

• Verge Genomics rebranded its AI drug discovery platform following a clinical trial setback.

• Kardigan Therapeutics filed for an initial public offering to advance its cardiovascular drug pipeline.